LANSING, MI, Sep 13, 2010 (MARKETWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of spider silk based materials, today updated its press release from September 7 by confirming that scientists working in collaboration with the Company have successfully genetically engineered silkworm moths with select spider genes.
The spider-moths were developed as a part of the Company's product development program that is aimed at utilizing transgenic silkworms to produce spider silk. The Company believes that spider silk has numerous potential commercial and industrial applications in the hundred billion dollar technical textiles market.
The silkworms were successfully genetically engineered with the Company's targeted spider silk DNA sequences.
"In response to the feedback from our September 7th press release regarding genetically engineered silkworm, we are happy to readdress our press release here in layman's terms. While transgenic silkworm is the proper scientific term, laymen may better understand what we have accomplished as genetically engineered spider-moths," said CEO Kim K. Thompson. "The genetically engineered silkworms are true moths which have been transformed with only one carefully targeted spider silk gene sequence. That gene sequence relates specifically to silk production."
Thompson added, "We believe that the spider DNA has fully integrated into the silkworm chromosome. This genetic engineering success clears a major hurdle in our path; it puts us well ahead of our product development schedule and will allow us to further accelerate product development."
The Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month.
For more information on Kraig Biocraft Laboratories please visit the Company's web site: www.KraigLabs.com
This press release includes certain statements that may be deemed to be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.
CONTACT: Kraig Biocraft Laboratories, Inc. Kim K. Thompson CEO (517) 336-0807 Email Contact
Posts
No comments:
Post a Comment